Avaam (amlodipine + valsartan): Uses, Dosage & Side Effects

What it's for (Indications)

Amlodipine/valsartan combination therapy is clinically indicated for the management of essential hypertension in adult patients.
This medication is typically prescribed when blood pressure is not adequately controlled with monotherapy (either amlodipine or valsartan alone), or it may be initiated as a first-line treatment in patients who are likely to require multiple antihypertensive agents to achieve their blood pressure goals.
By combining two distinct mechanisms of action, it offers a synergistic approach to lowering elevated blood pressure, thereby reducing the risk of cardiovascular events such as stroke and myocardial infarction.
The decision to initiate this combination therapy should be based on a comprehensive assessment of the patient's cardiovascular risk profile and current blood pressure control.

Dosage Information

Type	Guideline
Standard	The dosage of amlodipine/valsartan must be individualized based on the patient's clinical response and tolerability, aiming to achieve optimal blood pressure control. This fixed-dose combination is administered orally once daily. Available strengths typically range from amlodipine 5 mg/valsartan 80 mg up to amlodipine 10 mg/valsartan 320 mg. The recommended starting dose should consider the patient's previous antihypertensive regimen and their blood pressure response. If a patient is not adequately controlled on monotherapy, titration to the appropriate fixed-dose combination is warranted. Maximum antihypertensive effects are generally observed within two weeks following a dose change. Dosage adjustments should proceed cautiously, particularly in elderly patients or those with impaired renal or hepatic function, to minimize potential adverse effects and ensure patient safety.

Type

Guideline

Standard

The dosage of amlodipine/valsartan must be individualized based on the patient's clinical response and tolerability, aiming to achieve optimal blood pressure control. This fixed-dose combination is administered orally once daily. Available strengths typically range from amlodipine 5 mg/valsartan 80 mg up to amlodipine 10 mg/valsartan 320 mg. The recommended starting dose should consider the patient's previous antihypertensive regimen and their blood pressure response. If a patient is not adequately controlled on monotherapy, titration to the appropriate fixed-dose combination is warranted. Maximum antihypertensive effects are generally observed within two weeks following a dose change. Dosage adjustments should proceed cautiously, particularly in elderly patients or those with impaired renal or hepatic function, to minimize potential adverse effects and ensure patient safety.

Safety & Warnings

Common Side Effects

Patients receiving amlodipine/valsartan may experience a range of side effects, although many are mild and transient.
Commonly reported adverse reactions include peripheral edema (attributable to amlodipine's vasodilatory effects), headache, dizziness, fatigue, and nasopharyngitis.
Less frequently, but of significant clinical concern, are episodes of symptomatic hypotension, particularly in volume-depleted individuals.
Hyperkalemia can occur due to the valsartan component, especially in patients with renal impairment or those concurrently using potassium-sparing diuretics or potassium supplements.
Renal function deterioration, including acute renal failure, may also be observed, predominantly in patients with pre-existing renal disease or severe congestive heart failure.
Rarely, angioedema (swelling of the face, lips, tongue, and/or pharynx) can develop, requiring immediate medical attention.
Any unusual or severe symptoms should be reported to a healthcare professional.

Serious Warnings

Black Box Warning: **FETAL TOXICITY:** When pregnancy is detected, amlodipine/valsartan should be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. There have been several reports in the medical literature describing fetal abnormalities, oligohydramnios, fetal hypotension, and fetal death when angiotensin II receptor blockers (ARBs) were administered during the second and third trimesters of pregnancy. Oligohydramnios, resulting from decreased fetal renal function, may be associated with fetal lung hypoplasia, skeletal deformations, and patent ductus arteriosus. Potential adverse effects on the neonate include hypotension, hyperkalemia, and renal failure. These adverse outcomes are generally associated with the use of ARBs during the second and third trimesters of pregnancy. However, exposure to ARBs during the first trimester has also been associated with an increased risk of major congenital malformations. Therefore, women of childbearing potential should be made aware of the potential risks and counselled to use effective contraception while on this therapy. If pregnancy occurs, the medication should be stopped immediately.
Several critical warnings are associated with amlodipine/valsartan therapy.
Symptomatic hypotension may occur, especially in patients who are volume-depleted (e.
g.
, those on high-dose diuretics) or salt-depleted.
Patients should be adequately hydrated before initiating therapy.
Special caution is advised in patients with severe aortic stenosis or hypertrophic obstructive cardiomyopathy, where vasodilatation could exacerbate outflow obstruction.
The valsartan component can lead to renal function impairment, particularly in patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system (RAAS), such as those with severe congestive heart failure or bilateral renal artery stenosis.
Therefore, periodic monitoring of renal function and serum potassium levels is recommended.
Dual blockade of the RAAS using ARBs, ACE inhibitors, or aliskiren is contraindicated in patients with diabetes and generally not recommended in other patients due to increased risks of hypotension, hyperkalemia, and renal function changes.
Worsening angina and acute myocardial infarction have been reported rarely upon initiation or dosage increase of amlodipine, particularly in patients with severe obstructive coronary artery disease.

How it Works (Mechanism of Action)

Amlodipine/valsartan is a combination antihypertensive medication that leverages two distinct pharmacological mechanisms to achieve blood pressure reduction. Amlodipine, a dihydropyridine calcium channel blocker, selectively inhibits the transmembrane influx of calcium ions into vascular smooth muscle and, to a lesser extent, cardiac muscle. This action results in peripheral arterial vasodilation, which reduces peripheral vascular resistance and, consequently, lowers blood pressure. Amlodipine's effect is primarily on systemic arterial resistance vessels. Valsartan, an angiotensin II receptor blocker (ARB), works by selectively blocking the binding of angiotensin II to the AT1 receptor, which is responsible for the physiological effects of angiotensin II, including vasoconstriction, aldosterone synthesis and secretion, cardiac stimulation, and renal reabsorption of sodium. By blocking the AT1 receptor, valsartan effectively counteracts the pressor effects of angiotensin II, leading to vasodilation, reduced aldosterone secretion, and increased sodium and water excretion, thereby lowering blood pressure. The complementary actions of amlodipine and valsartan provide superior blood pressure control compared to either agent alone, addressing different pathways involved in hypertension.